Stemline Therapeutics Inc (NASDAQ:STML)

Data as of Jan 27
 +0.73 / +5.40%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing oncology therapeutics that target both cancer stem cells and tumor bulk. It currently developing two clinical stage products: SL-401 and SL-701. The lead indication for SL-401, a biologic targeted therapy is acute myeloid leukemia. The lead indications for SL-701, a therapeutic cancer vaccine comprised of synthetic peptides that correspond to specific targets, called epitopes, on cancer stem cells and tumor bulk of brain cancer, are pediatric and adult brain cancer. It also develops a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Contact Information

Stemline Therapeutics, Inc.
750 Lexington Avenue
New York New York 10022
P:(646) 502-2310
Investor Relations:



Mutual fund holders38.79%
Individual stakeholders16.70%
Other institutional15.62%

Top Executives

Ivan BergsteinChairman, President & Chief Executive Officer
Kenneth HobermanChief Operating Officer & Secretary
David G. GioncoChief Accounting Officer & Vice President-Finance
Eric K. RowinskyChief Medical Officer, Head-Research & Development
Michael SzarekHead-Clinical & Regulatory Affairs

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.